Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurocognitive effects of lorlatinib in ALK/ROS1-positive NSCLC
NL-OMON27508Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Primary endpoint: Change in each neurocognitive endpoint from baseline during lorlatinib treatment. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON27508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27508.